Please login to the form below

Not currently logged in
Email:
Password:

Debiopharm

This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset

Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset

Development and commercialisation deal could be worth up to $1.08bn. German company Merck KGaA has signed an exclusive licence agreement with Swiss biopharma company Debiopharm for its late-stage oncology ... Merck KGaA will pay Debiopharm 188m upfront

Latest news

  • Merck and Roche team up for hepatitis C studies

    Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's

  • More Eloxatin settlements for sanofi-aventis

    Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.

  • Sanofi-aventis settles Eloxatin lawsuits

    medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.

  • Novartis gain rights to hepatitis C drug

    The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).

  • HCV hope on the horizon

    The ciclosporin analogue DEBIO 025 (Debiopharm) is a first-in-class cyclophilin inhibitor that has been generally well tolerated in clinical trials to date and may have potential as an addition

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics